Table 2.
Difference between the expected and observed number of first diagnoses or first prescriptions between March 1 and May 31, 2020
| Expected cases, n (95% CI) | Observed cases, n | Percentage reduction in cases, % (95% CI)* | |
|---|---|---|---|
| Type 2 diabetes | 276 (185 to 382) | 141 | 49·0% (23·8 to 63·1) |
| Metformin | 331 (248 to 422) | 213 | 35·7% (14·1 to 49·5) |
| Circulatory system disease | 1054 (850 to 1286) | 598 | 43·3% (29·6 to 53·5) |
| Aspirin 75 mg | 301 (228 to 381) | 213 | 29·3% (6·6 to 44·1) |
| Calcium channel blockers | 558 (452 to 668) | 359 | 35·6% (20·6 to 46·3) |
| ACEIs | 518 (414 to 632) | 249 | 52·0% (39·9 to 60·6) |
| Clopidogrel | 265 (179 to 367) | 148 | 44·2% (17·3 to 59·7) |
| Common mental health problems | 2147 (1821 to 2489) | 1073 | 50·0% (41·1 to 56·9) |
| SSRIs | 737 (593 to 889) | 449 | 39·1% (24·3 to 49·5) |
| Malignant cancer | 194 (138 to 257) | 163 | 16·0% (−18·1 to 36·6) |
Expected numbers of first diagnoses and prescriptions were generated using negative binomial regression models. ACEIs=angiotensin-converting enzyme inhibitors. SSRIs=selective serotonin reuptake inhibitors.
*
Expected cases minus observed cases.